wbldb
home
|
authors
|
theses
Black, Dennis M.
1
;
Sellmeyer, Deborah E.
2
Now that you can get what you want, can you keep what you need?
J Bone Miner Res
. February 2020;35(2):217-218
©2019 American Society for Bone and Mineral Research
Affiliations
1
Department of Epidemiology and Biostatistics,
University of California San Francisco
, San Francisco, CA, USA
2
Division of Endocrinology, Gerontology and Metabolism, Stanford, CA, USA
Links
DOI:
10.1002/jbmr.3914
PubMed:
31845376
WoS:
000502862000001
History
Received: 2019-09-30
Revised: 2019-10-22
Accepted: 2019-11-02
Cited Works (12)
Year
Entry
2017
Anastasilakis AD, Polyzos SA, Makras P, Aubry-Rozier B, Kaouri S, Lamy O. Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases.
J Bone Miner Res
. June 2017;32(6):1291-1296.
2017
Reid IR, Horne AM, Mihov B, Gamble GD. Bone loss after denosumab: only partial protection with zoledronate.
Calcif Tiss Int
. October 2017;101(4):371-374.
2007
Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR; HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.
NEJM
. May 3, 2007;356(18):1809-1822.
2005
Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L, Hue T, Lang TF, McGowan JA, Rosen CJ; PaTH Study Investigators. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis.
NEJM
. August 11, 2005;353(6):555-565.
2012
Freemantle N, Satram-Hoang S, Tang E-T, Kaur P, Macarios D, Siddhanti S, Borenstein J, Kendler DL; DAPS Investigators. Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women.
Osteoporos Int
. January 2012;23(1):317-326.
2017
Tsourdi E, Langdahl B, Cohen-Solal M, Aubry-Rozier B, Eriksen EF, Guañabens N, Obermayer-Pietsch B, Ralston SH, Eastell R, Zillikens MC. Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS.
Bone
. December 2017;105:11-17.
2009
Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C; FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis.
NEJM
. August 20, 2009;361(8):756-765.
2016
Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, Alexandersen P, Zerbini CAF, Hu M-y, Harris AG, Fitzpatrick LA, Cosman F, Christiansen C; ACTIVE Study Investigators. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial.
JAMA
. August 16, 2016;316(7):722-733.
2017
Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A. Romosozumab or alendronate for fracture prevention in women with osteoporosis.
NEJM
. October 12, 2017;377(15):1417-1427.
2008
Miller PD, Bolognese MA, Lewiecki EM, McClung MR, Ding B, Austin M, Liu Y, San Martin J; AMG 162 Bone Loss Study Group. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial.
Bone
. August 2008;43(2):222-229.
2016
Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, Hofbauer LC, Lau E, Lewiecki EM, Miyauchi A, Zerbini CAF, Milmont CE, Chen L, Maddox J, Meisner PD, Libanati C, Grauer A. Romosozumab treatment in postmenopausal women with osteoporosis.
NEJM
. October 20, 2016;375(16):1532-1543.
2018
McClung MR, Brown JP, Diez‐Perez A, Resch H, Caminis J, Meisner P, Bolognese MA, Goemaere S, Bone HG, Zanchetta JR, Maddox J, Bray S, Grauer A. Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density: a randomized, double‐blind, phase 2, parallel group study.
J Bone Miner Res
. August 2018;33(8):1397-1406.